Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + Temozolomide + Anti-PD-1 in R/R PCNSL
NCT06556199Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in primary central nervous system lymphoma (PCNSL), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Aug 2024; status: recruiting.
02
Drugs
selinexor
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT06556199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06556199.